Spine Biologics Market

Spine Biologics Market - Global Market Share, Trends, Analysis and Forecast, 2023-2032
Frequently asked questions about this report

The spine biologics market is expected to reach US$ 3.42 Billion by 2032.

The spine biologics market is expected grow at a CAGR of 4.7% between 2023 to 2032

The spine biologics market was estimated to be US$ 2.16 Billion in 2022.

North America is expected to dominate the global spine biologics market due to factors such as the presence of advanced healthcare infrastructure, high healthcare expenditure, and a large patient population with spinal disorders.

The global spine biologics market is being driven by several key factors including, increasing prevalence of spinal disorders and conditions, rising demand for minimally invasive surgical procedures and growing aging population worldwide contributes to the demand for spine biologics.

AlloSource (United States), Amedica Corporation (United States), Baxter International Inc. (United States), DePuy Synthes (a subsidiary of Johnson & Johnson) (United States), Exactech, Inc. (United States), Globus Medical, Inc. (United States), Integra LifeSciences Corporation (United States), Medtronic plc (Ireland), NuVasive, Inc. (United States), Orthofix Medical Inc. (United States), RTI Surgical Holdings, Inc. (United States), SeaSpine Holdings Corporation (United States), Stryker Corporation (United States), Zimmer Biomet Holdings, Inc. (United States), Xtant Medical Holdings, Inc. (United States) among others, are the major players in this market.

The global spine biologics market segmented on the basis of product type, patient type, biomaterial, end user, application and geography.

PLIF procedure is the largest application segment in the spine biologics market. PLIF is a commonly performed surgical technique for achieving spinal fusion and addressing various lumbar spine conditions, such as degenerative disc disease, spondylolisthesis, and spinal stenosis.